Skip to content
StackItSmart
AHuman RCT or meta-analysis

Beta-Alanine

Beta-alanine is a non-proteinogenic amino acid taken orally as an ergogenic dietary supplement. It is the rate-limiting precursor to muscle carnosine, an intracellular pH buffer, and is used to modestly improve high-intensity exercise capacity in the ~1-4 minute range. It is not a hormone, anabolic agent, or fat-loss drug and has no effect on muscle mass or body composition on its own. The headline and near-universal side effect is paraesthesia - harmless but sometimes intense tingling/prickling of the face, scalp, neck, and hands that begins within minutes of a large dose. This is unpleasant but self-limiting. Human safety data at 4-6 g/day for weeks-to-months are reassuring, with no established organ toxicity, but long-term (multi-year) and high-dose safety data are limited, and the modest, exercise-specific performance benefit should be weighed against those unknowns. Effect sizes in meta-analyses are small and inconsistent, and washout is long because muscle carnosine decays over weeks.

Clinical readoutAncillary · ergogenic
Hepatic strainLow
CardiovascularNone
HPTA suppressionNone
Half-life
38 min
Route
Oral
Evidence
A
Active
Acute plasma exposure l…
38 min1.3 h1.9 h2.5 h3.1 h
Illustrative single-compartment washout · each mark = one half-life · t½ ≈ Plasma beta-alanine is cleared rapidly; after oral doses of 10-40 mg/kg, plasma concentrations peak within ~30-45 min and return to baseline by ~2 hours (short plasma half-life on the order of tens of minutes). The functionally relevant pool - muscle carnosine - turns over very slowly, with washout over many weeks after cessation.
Pharmacology

Mechanism of action

Beta-alanine is the rate-limiting substrate for synthesis of the dipeptide carnosine (beta-alanyl-L-histidine) in skeletal muscle. Chronic oral supplementation (4-6 g/day for at least 2-4 weeks) raises intramuscular carnosine by roughly 40-65%. Elevated carnosine acts as an intracellular proton (H+) buffer during high-intensity glycolytic exercise, attenuating the fall in muscle pH and thereby delaying acidosis-related fatigue; carnosine may also contribute antioxidant and calcium-sensitivity effects. The benefit is mediated by the accumulated muscle carnosine pool, not by acute plasma beta-alanine. The characteristic paraesthesia is a transient sensory effect attributed to activation of cutaneous sensory neurons (Mas-related G-protein-coupled receptors) by circulating beta-alanine after a bolus dose.
Kinetics

Pharmacokinetics

Half-life

Plasma beta-alanine is cleared rapidly; after oral doses of 10-40 mg/kg, plasma concentrations peak within ~30-45 min and return to baseline by ~2 hours (short plasma half-life on the order of tens of minutes). The functionally relevant pool - muscle carnosine - turns over very slowly, with washout over many weeks after cessation.

Active duration

Acute plasma exposure lasts ~2 hours per dose. The ergogenic effect depends on accumulated muscle carnosine, which builds over 2-4+ weeks of daily dosing and declines gradually over roughly 6-15 weeks after stopping (long skeletal-muscle carnosine washout).

Route

Oral (capsules, tablets, powder; sustained-release formulations exist to blunt paraesthesia).

Metabolism & clearance

Absorbed from the gut into plasma; taken up by skeletal muscle via beta-amino acid transporters and incorporated into carnosine by carnosine synthase. Urinary loss of intact beta-alanine is small (<5% of an oral dose). Excess/unused beta-alanine is largely metabolized; renal excretion of the parent compound is minor.

For monitoring and washout planning, not drug-test evasion.

Reported effects

Physiological & performance effects

  • Increases skeletal muscle carnosine concentration by approximately 40-65% after 4 weeks of 4-6 g/day
  • Small overall improvement in high-intensity exercise capacity/performance (pooled effect size ~0.18), with the most consistent benefit in tasks lasting roughly 1-4 minutes
  • Benefit is greater for exercise capacity (time-to-exhaustion) than for closed-loop time-trial performance, and negligible for efforts under ~60 seconds or prolonged endurance beyond ~25 minutes
  • May attenuate neuromuscular fatigue, with some evidence of larger effects in older adults
  • No independent effect on strength, muscle mass, body composition, or fat loss
  • Effect on intense endurance events is trivial and non-significant in at least one focused meta-analysis (ES ~0.17, not statistically significant)
Safety

Adverse effects by system

Cardiovascular

No established cardiovascular adverse effects in humans at studied doses; meta-analytic safety review found no signal of cardiovascular harm. Long-term cardiovascular data are limited.

Hepatic

No clinically significant hepatotoxicity reported. A meta-analysis detected a small statistically-significant rise in circulating alanine aminotransferase (ALT), but mean values remained well within clinical reference ranges and are of uncertain clinical relevance.

Endocrine / HPTA

No known endocrine or hypothalamic-pituitary-testicular (HPTA) activity. Beta-alanine is not a hormone or steroid and has no described effect on testosterone, gonadotropins, or the HPTA axis.

Reproductive

No known effect on reproductive function or fertility; no adequate human data suggesting reproductive harm, and no plausible hormonal mechanism.

Neuropsychiatric

No established psychiatric adverse effects. The transient paraesthesia can be uncomfortable/anxiety-provoking for some users but is a sensory phenomenon, not a psychiatric effect. No human data support neuropsychiatric harm.

Renal

No established renal toxicity in humans at studied doses; urinary excretion of the parent compound is minimal. No renal safety signal in the systematic risk assessment.

Hematologic

No established hematologic adverse effects; safety review found no adverse effect on health-related blood biomarkers beyond the small ALT change noted above. Theoretical competition with taurine uptake did not translate into measurable muscle taurine depletion in humans.

Dermatologic

Paraesthesia (tingling, prickling, sometimes itching or a flushing sensation of the skin of the face, scalp, neck, chest, and hands) is the only consistently reported side effect; it is dose-dependent, begins within minutes of a bolus, and resolves within roughly 60-90 minutes. It is benign and can be reduced by using smaller divided doses (~0.8-1.6 g) or sustained-release formulations.

Recovery

HPTA suppression & recovery

Suppression: None - beta-alanine has no known effect on the HPTA axis

Beta-alanine is not hormonally active and does not suppress endogenous testosterone or gonadotropins, so no HPTA recovery or post-cycle intervention is indicated or applicable. SERM therapy is not relevant to this compound. Any concurrent HPTA concerns arising from other agents a user may be taking should be evaluated and managed by a qualified endocrinologist; do not use beta-alanine as an HPTA or recovery agent.

Bloodwork & vitals

Monitoring

Recommended labs & checks
Baseline and periodic liver function tests (ALT, AST) given the small meta-analytic ALT signal, particularly with prolonged or higher-than-studied useBasic metabolic panel including renal function (creatinine, eGFR) as general due diligence for any chronic supplementComplete blood count as part of routine health monitoring

Cadence: Baseline before starting; recheck at roughly 3-6 months if using chronically, or sooner if symptoms arise. Most users of standard doses for defined training blocks will not require lab monitoring, but bloodwork with a clinician is the responsible default for ongoing use.

Warning signs — seek care
  • Severe, prolonged, or spreading paraesthesia that does not resolve within a couple of hours, or paraesthesia occurring without recent dosing
  • Any allergic-type reaction (rash, hives, swelling, difficulty breathing) - stop immediately and seek emergency care
  • Jaundice, dark urine, right-upper-quadrant pain, or unexplained fatigue (possible liver issue) - stop and see a clinician
  • New or unexplained numbness/neurological symptoms - seek medical evaluation rather than attributing them to the supplement
Do not use if

Contraindications

  • Known hypersensitivity to beta-alanine or a supplement formulation ingredient
  • Users who find the paraesthesia intolerable or who have conditions in which transient paraesthesia would mask or mimic important symptoms (e.g., certain neurological conditions) should avoid or use only under clinician guidance
  • Pregnancy and lactation: no adequate human safety data - avoid
  • Children/adolescents: no adequate safety data - avoid
  • Caution or clinician oversight in anyone with pre-existing liver or kidney disease, given limited data in these populations
  • Not a substitute for medical evaluation; anyone with unexplained symptoms should see a clinician rather than self-treat
Combinations

Interaction profile

  • ContraindicatedWith DNP: Additive cardiovascular strain

Check a specific combination in the interaction checker.

Harm reduction

Reducing harm & when to stop

  • Paraesthesia is expected, harmless, and self-limiting; if it is bothersome, using smaller divided doses (~0.8-1.6 g) or a sustained-release formulation substantially reduces it - this is a comfort measure, not a performance optimization
  • There is no acute benefit to a single large dose; the effect depends on gradual muscle carnosine accumulation, so large boluses only increase tingling without added benefit
  • Stop and seek medical care for any allergic reaction, for paraesthesia that is severe/prolonged or occurs without dosing, or for signs of liver problems (jaundice, dark urine, right-upper-quadrant pain)
  • Do not use beta-alanine to mask fatigue while ignoring pain, injury, or overtraining; it does not protect against those
  • Avoid in pregnancy, breastfeeding, and in adolescents due to absent safety data; get clinician guidance if you have liver or kidney disease
  • Use third-party-tested products and discuss chronic supplement use and periodic bloodwork with a clinician; supplements are not a substitute for medical care
  • Beta-alanine has no hormonal or recovery ('post-cycle') role - do not use it for that purpose, and consult an endocrinologist for any HPTA concerns from other agents
Evidence

Citations (6)

Every clinical claim above is tied to a primary source. Overall evidence grade A — graded to the best available evidence for its core claims.

  1. 01

    Four weeks of beta-alanine 4-6 g/day significantly augments muscle carnosine, acting as an intracellular pH buffer; the only reported side effect is paraesthesia, which can be attenuated by divided lower doses (~1.6 g) or sustained-release formulations; benefit is most pronounced in tasks lasting 1-4 minutes; appears safe in healthy populations at recommended doses.

    GuidelinePMID 26175657 ↗

  2. 02

    Meta-analysis of 40 studies (1461 participants) found a small but significant overall ergogenic effect size of 0.18 (95% CI 0.08-0.28), moderated by exercise duration, with greater effects on exercise capacity than performance in the 0.5-10 minute window.

    Meta-analysisPMID 27797728 ↗

  3. 03

    Systematic risk assessment and meta-analysis (101 human, 50 animal studies) found paraesthesia the only reported side effect (OR 8.9 vs placebo), a small increase in circulating ALT that remained within clinical reference ranges, no effect on skeletal muscle taurine or histidine in humans, and no evidence of adverse health effects at doses used in research.

    Meta-analysisPMID 30980076 ↗

  4. 04

    Meta-analysis found beta-alanine improved exercise outcomes vs placebo (median ~2.85% improvement), with benefit for exercise lasting 60-240 s and >240 s but not <60 s, and improvement in exercise capacity rather than performance.

    Meta-analysisPMID 22270875 ↗

  5. 05

    Focused meta-analysis of intense endurance performance (45 s to 8 min) found only a trivial, non-significant effect of beta-alanine (ES 0.17, 95% CI -0.12 to 0.46, p=0.24), unlike caffeine and bicarbonate.

    Meta-analysisPMID 28536531 ↗

  6. 06

    Oral beta-alanine peaks in plasma within ~30-45 min and returns to baseline by ~2 h, with <5% urinary loss; supplementation of 3.2-6.4 g/day for 4 weeks increased muscle carnosine by ~42-64%, and plasma taurine rose without increased urinary taurine loss.

    RCTPMID 16554972 ↗

Last reviewed 2026-07-06 · Verified against PubMed · Educational, not medical advice